Medicine
Pemetrexed 500 mg/20 mL powder for injection
Pemetrexed 500 mg/20 mL powder for injection is a generic prescription medicine for intravenous use, made by 7 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store powder at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to…
Key facts
- Active ingredient (INN)
- Pemetrexed
- Brand
- Sold under the generic name
- Strength
- 500 mg/20 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial and 17 more
- Manufacturers
- Dr. Reddy's LaboratoriesIndiaBluePoint LaboratoriesFresenius KabiMeitheal PharmaceuticalsAvyxa PharmaSomerset TherapeuticsWaverley Pharma
- Origin register
- US FDA, United States
- Storage
- Store powder at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store reconstituted and infusion solutions at refrigerated, 2°C to 8°C (36°F to 46°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BA04 Pemetrexed
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 June 2018
- Identifiers
- RxCUI 2602136, 1728072, 1728077 +1DailyMed set ID 14974d4e-2f01-4e02-aea2-c28b3ca0781c, 4cc1574b-3d2f-489b-9ad3-55695bb97200, 39219e4b-80a6-4d4f-96a3-1202e542d050 +6NDC 68001-545, 68001-543, 70069-835 +17Application ANDA209851, ANDA203774, ANDA211899 +5
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 40 mL in 1 vial, single-dose | 43598-370-74 | Dr. Reddy's LaboratoriesIndia | 25 May 2022 |
| 1 vial, single-dose in 1 carton / 4 mL in 1 vial, single-dose | 43598-386-62 | Dr. Reddy's LaboratoriesIndia | 25 May 2022 |
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 43598-387-11 | Dr. Reddy's LaboratoriesIndia | 25 May 2022 |
| 1 vial, single-use in 1 carton / 4 mL in 1 vial, single-use | 63323-134-10 | Fresenius Kabi | 25 May 2022 |
| 1 vial, single-use in 1 carton / 20 mL in 1 vial, single-use | 63323-450-50 | Fresenius Kabi | 25 May 2022 |
| 1 vial, single-use in 1 carton / 30 mL in 1 vial, single-use | 63323-621-00 | Fresenius Kabi | 25 May 2022 |
| 1 vial, single-use in 1 carton / 40 mL in 1 vial, single-use | 63323-622-00 | Fresenius Kabi | 25 May 2022 |
| 1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 71288-146-50 | Meitheal Pharmaceuticals | 13 December 2022 |
| 1 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 71288-147-50 | Meitheal Pharmaceuticals | 13 December 2022 |
| 1 vial, single-dose in 1 carton / 40 mL in 1 vial, single-dose | 71288-148-51 | Meitheal Pharmaceuticals | 13 December 2022 |
| 1 vial in 1 carton / 4 mL in 1 vial | 83831-111-01 | Avyxa Pharma | 1 January 2025 |
| 1 vial in 1 carton / 20 mL in 1 vial | 83831-112-01 | Avyxa Pharma | 1 January 2025 |
| 1 vial in 1 carton / 4 mL in 1 vial | 70069-834-01 | Somerset Therapeutics | 15 April 2025 |
| 1 vial in 1 carton / 20 mL in 1 vial | 70069-835-01 | Somerset Therapeutics | 15 April 2025 |
| 1 vial in 1 carton / 4 mL in 1 vial | 72338-100-01 | Waverley Pharma | 4 June 2018 |
| 1 vial in 1 carton / 20 mL in 1 vial | 72338-101-01 | Waverley Pharma | 4 June 2018 |
| 1 vial in 1 carton / 4 mL in 1 vial | 68001-543-41 | BluePoint Laboratories | 1 September 2022 |
| 1 vial in 1 carton / 20 mL in 1 vial | 68001-544-41 | BluePoint Laboratories | 1 September 2022 |
| 1 vial in 1 carton / 30 mL in 1 vial | 68001-545-41 | BluePoint Laboratories | 1 September 2023 |
| 1 vial in 1 carton / 40 mL in 1 vial | 68001-546-41 | BluePoint Laboratories | 1 September 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pemetrexed
Clinical summary
Pemetrexed is a folate analog metabolic inhibitor indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. MedsAcross supplies Pemetrexed for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PemetrexedFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Alimta prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Alimta: European public assessment report (EPAR) · European Medicines Agency
- Armisarte (previously Pemetrexed Actavis): European public assessment report (EPAR) · European Medicines Agency
Need Pemetrexed 500 mg/20 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.